Soluble guanylate cyclase as a novel treatment target for osteoporosis

Endocrinology (United States)

Volumn 155, Issue 12, 2014, Pages 4720-4730

  Jisha, Joshua ^a   Schwaerzer, Gerburg K ^a   Kalyanaraman, Hema ^a   Cory, Esther ^b   Sah, Robert L ^c   Li, Mofei ^c   Vaida, Florin ^c   Boss, Gerry R ^a   Pilz, Renate B ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOIC ACID DERIVATIVE; CINACIGUAT; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENZYME ACTIVATOR; GUANYLATE CYCLASE;

ANIMAL; BLOOD; BONE REMODELING; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; FEMALE; HUMAN; MALE; METABOLISM; OSTEOBLAST; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; RANDOMIZATION;

ANIMALS; BENZOATES; BONE REMODELING; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATORS; FEMALE; GUANYLATE CYCLASE; HUMANS; MALE; MICE, INBRED C57BL; OSTEOBLASTS; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; RANDOM ALLOCATION;

EID: 84914162800     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1343     Document Type: Article

References (62)

1. Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010;16(suppl 3):1-37.
2. Kawai M, Mödder UI, Khosla S, Rosen CJ. Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov. 2011;10:141-156.
3. Khosla S, Melton LJ 3rd, Riggs BL. The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res. 2011;26:441-451.
4. Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev. 2010;31:266-300.
5. Tomkinson A, Reeve J, Shaw RW, Noble BS. The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J Clin Endocrinol Metab. 1997;82:3128-3135.
6. Bouxsein ML, Myers KS, Shultz KL, Donahue LR, Rosen CJ, Beamer WG. Ovariectomy-induced bone loss varies among inbred strains of mice. J Bone Miner Res. 2005;20:1085-1092.
7. Levis S, Theodore G. AHRQ's comparative effectiveness review of treatments to prevent fractures in men and women with low bone density or osteoporosis: a summary of the key findings. J Manag Care Pharm. 2012;18(4 suppl B):S3-S13.
8. Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res. 2014;29:1929-1937.
9. Russell KS, Haynes MP, Sinha D, Clerisme E, Bender JR. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc Natl Acad Sci USA. 2000;97:5930-5935.
10. Mendelsohn ME, Karas RH. Rapid progress for non-nuclear estrogen receptor signaling. J Clin Invest. 2010;120:2277-2279.
11. Armour KE, Armour KJ, Gallagher ME, et al. Defective bone formation and anabolic response to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide synthase. Endocrinology. 2001;142:760-766.
12. Grassi F, Fan X, Rahnert J, et al. Bone re/modeling is more dynamic in the endothelial nitric oxide synthase(-/-) mouse. Endocrinology. 2006;147:4392-4399.
13. Wimalawansa SJ, De Marco G, Gangula P, Yallampalli C. Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone. 1996;18:301-304.
14. Hukkanen M, Platts LA, Lawes T, et al. Effect of nitric oxide donor nitroglycerin on bone mineral density in a rat model of estrogen deficiency-induced osteopenia. Bone. 2003;32:142-149.
15. Jamal SA, Browner WS, Bauer DC, Cummings SR. Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures. J Bone Miner Res. 1998;13:1755-1759.
16. Rejnmark L, Vestergaard P, Mosekilde L. Decreased fracture risk in users of organic nitrates: a nationwide case-control study. J Bone Miner Res. 2006;21:1811-1817.
17. Pouwels S, Lalmohamed A, van Staa T, et al. Use of organic nitrates and the risk of hip fracture: a population-based case-control study. J Clin Endocrinol Metab. 2010;95:1924-1931.
18. Jamal SA, Hamilton CJ, Eastell R, Cummings SR. Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: a randomized trial. JAMA. 2011;305:800-807.
19. Wimalawansa SJ, Grimes JP, Wilson AC, Hoover DR. Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss. J Clin Endocrinol Metab. 2009;94:3356-3364.
20. Jamal SA, Hamilton CJ. Nitric oxide donors for the treatment of osteoporosis. Curr Osteoporos Rep. 2012;10:86-92.
21. Parker JD. Nitrate tolerance, oxidative stress, and mitochondrial function: another worrisome chapter on the effects of organic nitrates. J Clin Invest. 2004;113:352-354.
22. Marathe N, Rangaswami H, Zhuang S, Boss GR, Pilz RB. Prosurvival effects of 17β-estradiol on osteocytes are mediated by nitric oxide/cGMP via differential actions of cGMP-dependent protein kinases I and II. J Biol Chem. 2012;287:978-988.
23. Rangaswami H, Schwappacher R, Marathe N, et al. Cyclic GMP and protein kinase G control a Src-containing mechanosome in osteoblasts. Sci Signal. 2010;3:ra91.
24. Mancini L, Moradi-Bidhendi N, Becherini L, Martineti V, MacIntyre I. The biphasic effects of nitric oxide in primary rat osteoblasts are cGMP dependent. Biochem Biophys Res Commun. 2000;274: 477-481.
25. Hagiwara H, Inoue A, Yamaguchi A, et al. cGMP produced in response to ANP and CNP regulates proliferation and differentiation of osteoblastic cells. Am J Physiol. 1996;270:C1311-C1318.
26. Salloum FN, Das A, Samidurai A, et al. Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide. Am J Physiol Heart Circ Physiol. 2012;302:H1347-H1354.
27. Bakker A, Klein-Nulend J. Osteoblast isolation from murine calvariae and long bones. Methods Mol Med. 2003;80:19-28.
28. Rangaswami H, Marathe N, Zhuang S, et al. Type II cGMP-dependent protein kinase mediates osteoblast mechanotransduction. J Biol Chem. 2009;284:14796-14808.
29. Dempster DW, Compston JE, Drezner MK, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2013;28:2-17.
30. O'Shaughnessy MC, Polak JM, Afzal F, et al. Nitric oxide mediates 17β-estradiol-stimulated human and rodent osteoblast proliferation and differentiation. Biochem Biophys Res Commun. 2000;277:604-610.
31. Scutt A, Reading L, Scutt N, Still K. Mineralizing fibroblast-colony-forming assays. Methods Mol Med. 2003;80:29-39.
32. Mödder UI, Sanyal A, Kearns AE, et al. Effects of loss of steroid receptor coactivator-1 on the skeletal response to estrogen in mice. Endocrinology. 2004;145:913-921.
33. Cui R, Iso H, Yamagishi K, et al. Relationship of urinary cGMP excretion with aging and menopausal status in a general population. J Atheroscler Thromb. 2009;16:457-462.
34. Hayashi T, Ito I, Kano H, Endo H, Iguchi A. Estriol (E3) replacement improves endothelial function and bone mineral density in very elderly women. J Gerontol A Biol Sci Med Sci. 2000;55:B183-B190; discussion B191-B193.
35. Seeger H, Petersen G, Schulte-Wintrop E, Teichmann AT, Mueck AO. Effect of two oral contraceptives containing ethinylestradiol and levonorgestrel on serum and urinary surrogate markers of endothelial function. Int J Clin Pharmacol Ther. 2002;40:150-157.
36. Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci USA. 2008;105:20764-20769.
37. Martin-Millan M, Almeida M, Ambrogini E, et al. The estrogen receptor-a in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol. 2010;24:323-334.
38. Nakamura T, Imai Y, Matsumoto T, et al. Estrogen prevents bone loss via estrogen receptor α and induction of Fas ligand in osteoclasts. Cell. 2007;130:811-823.
39. Alexander JM, Bab I, Fish S, et al. Human parathyroid hormone 1-34 reverses bone loss in ovariectomized mice. J Bone Miner Res. 2001;16:1665-1673.
40. Pierroz DD, Bonnet N, Baldock PA, et al. Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. J Biol Chem. 2010;285:28164-28173.
41. Hayashi M, Nakashima T, Taniguchi M, Kodama T, Kumanogoh A, Takayanagi H. Osteoprotection by semaphorin 3A. Nature. 2012;485:69-74.
42. Sophocleous A, Landao-Bassonga E, Van't Hof RJ, Idris AI, Ralston SH. The type 2 cannabinoid receptor regulates bone mass and ovari-ectomy-induced bone loss by affecting osteoblast differentiation and bone formation. Endocrinology. 2011;152:2141-2149.
43. Kousteni S, Bellido T, Plotkin LI, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 2001;104:719-730.
44. Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369:330-340.
45. Armour KE, Ralston SH. Estrogen upregulates endothelial constitutive nitric oxide synthase expression in human osteoblast-like cells. Endocrinology. 1998;139:799-802.
46. Stacey E, Korkia P, Hukkanen MV, Polak JM, Rutherford OM. Decreased nitric oxide levels and bone turnover in amenorrheic athletes with spinal osteopenia. J Clin Endocrinol Metab. 1998;83:3056-3061.
47. Rosselli M, Imthurn B, Keller PJ, Jackson EK, Dubey RK. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 β-estradiol and norethisterone acetate. A two-year follow-up study. Hypertension. 1995;25:848-853.
48. Nakamura Y, Moss AJ, Brown MW, Kinoshita M, Kawai C. Longterm nitrate use may be deleterious in ischemic heart disease: a study using the databases from two large-scale postinfarction studies. Multicenter Myocardial Ischemia Research Group. Am Heart J. 1999;138:577-585.
49. Stasch JP, Schmidt P, Alonso-Alija C, et al. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol. 2002;136:773-783.
50. van't Hof RJ, Macphee J, Libouban H, Helfrich MH, Ralston SH. Regulation of bone mass and bone turnover by neuronal nitric oxide synthase. Endocrinology. 2004;145:5068-5074.
51. Zheng H, Yu X, Collin-Osdoby P, Osdoby P. RANKL stimulates inducible nitric-oxide synthase expression and nitric oxide production in developing osteoclasts. An autocrine negative feedback mechanism triggered by RANKL-induced interferon-β via NF-κB that restrains osteoclastogenesis and bone resorption. J Biol Chem. 2006;281:15809-15820.
52. Brandi ML, Hukkanen M, Umeda T, et al. Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms. Proc Natl Acad Sci USA. 1995;92:2954-2958.
53. Ralston SH, Grabowski PS. Mechanisms of cytokine induced bone resorption: role of nitric oxide, cyclic guanosine monophosphate, and prostaglandins. Bone. 1996;19:29-33.
54. Holliday LS, Dean AD, Lin RH, Greenwald JE, Gluck SL. Low NO concentrations inhibit osteoclast formation in mouse marrow cultures by cGMP-dependent mechanism. Am J Physiol. 1997;272:F283-F291.
55. Yaroslavskiy BB, Li Y, Ferguson DJ, Kalla SE, Oakley JI, Blair HC. Autocrine and paracrine nitric oxide regulate attachment of human osteoclasts. J Cell Biochem. 2004;91:962-972.
56. Yaroslavskiy BB, Zhang Y, Kalla SE, et al. O-dependent osteoclast motility: reliance on cGMP-dependent protein kinase I and VASP. J Cell Sci. 2005;118:5479-5487.
57. Bartell SM, Han L, Kim HN, et al. Non-nuclear-initiated actions of the estrogen receptor protect cortical bone mass. Mol Endocrinol. 2013;27:649-656.
58. Alles N, Soysa NS, Hayashi J, et al. Suppression of NF-κB increases bone formation and ameliorates osteopenia in ovariectomized mice. Endocrinology. 2010;151:4626-4634.
59. Yadav VK, Balaji S, Suresh PS, et al. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med. 2010;16:308-312.
60. Duque G, Huang DC, Dion N, et al. Interferon-γ plays a role in bone formation in vivo and rescues osteoporosis in ovariectomized mice. J Bone Miner Res. 2011;26:1472-1483.
61. Tatsumi S, Ishii K, Amizuka N, et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab. 2007;5:464-475.
62. Dallas SL, Prideaux M, Bonewald LF. The osteocyte: an endocrine cell ... and more. Endocr Rev. 2013;34:658-690.